tbuckley/cabot-search huggingface dataset:
FRI0137 Prolactin in systemic lupus erythematosus
Authors: L Moszkorzova, C Dostal, J Marek, Z Lacinova, L Musilova
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Prolactin (PRL) is an anterior pituitary hormone which is known to stimulate humoral and cell mediated immune responses, and may have a role in the pathogenesis of systemic lupus erythematosus (SLE). <h3>Objectives</h3> To determine whether elevated serum prolactin associates the SLEDAI activity and/or specific organ involvement in SLE when recent reports have been till now discrepant. <h3>Methods</h3> Basal serum PRL levels were determined in 55 consecutive SLE patients (pts) (49 females, 6 males) and in 41 healthy controls (31 females, 10 males) by RIA method. The estimated normal values of serum PRL were 200 mUI/l for males and 450 mUI/l for females. <h3>Results</h3> The idiopathic hyperprolactinemia (hyper-PRL) was found in 7 SLE females (14,29%; 828,682 ± 391,410 mUI/l) and in 3 males (50,00%; 305,469 ± 65,751 mUI/l); and in one male in healthy controls (10,00%; 348,352 mUI/l) only. In remaining 42 SLE females and in 3 males PRL serum level was normal (365,783 ± 282,796 mUI/l; 142,854 ± 84,512 mUI/l). After 6 months repeatedly determined serum PRL in 2 females and 2 males with initial hyper-PRL, has shown normalisation in 1 female and 1 male. As to the proposed association between hyper-PRL and disease activity and specific organ involvement and presence of anti-ds-DNA there are some data on the Table 1. <h3>Conclusion</h3> There was significantly higher frequency of hyper-PRL in 55 SLE pts compared to 41 healthy controls (p &lt; 0,001). The value of serum PRL has normalised in 2 pts with hyper-PRL from 4 pts with initial hyper-PRL without any specific treatment after 6 months by repeated estimation. We document a new idiopathic hyper-PRL in 1 patient with normal initial serum PRL. The association between hyper-PRL and activity and/or specific organ involvement and presence of anti-ds-DNA was not statistically significant due to low number of observations. <h3>References</h3> Walker SE, <i>et al</i>. Effect of prolactin in stimulating disease activity in SLE. Proc NY Acad Sci 1998;840:762–72 Neidhart M. Prolactin in autoimmune diseases. Proc Soc Exp Bio Med. 1998;217:408–79
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
Authors: Dean A Fennell, Amy King, Seid Mohammed, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Adrian Nicholson, Cathy Richards, Peter Wells-Jordan, Gavin James Murphy, Anne Thomas, Dean Anthony Fennell, Amy King, Seid Mohammed, Amy Branson, Cassandra Brooks, Liz Darlison, Alan George Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Adrian Nicholson, Cathy Richards, Peter Wells-Jordan, Gavin James Murphy, Anne Thomas, Sarah Anthony, Vina Bhundia, Caroline Cowley, Charlotte Poile, Molly Scotland
Journal: The Lancet Respiratory Medicine (2021)
Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis
Authors: Giovanni E Ferreira, Andrew J McLachlan, Chung-Wei Christine Lin, Joshua R Zadro, Christina Abdel-Shaheed, Mary O’Keeffe, Chris G Maher
Journal: BMJ (2021)

Abstract Objective To investigate the efficacy and safety of antidepressants for back and osteoarthritis pain compared with placebo. Design Systematic review and meta-analysis. Data sources Medline, Embase, Cochrane Central Register of Controlled Trials, CINAHL, International Pharmaceutical Abstracts, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform from inception to 15 November and updated on 12 May 2020. Eligibility criteria for study selection Randomised controlled trials comparing the efficacy or safety, or both of any antidepressant drug with placebo (active or inert) in participants with low back or neck pain, sciatica, or hip or knee osteoarthritis. Data extraction and synthesis Two independent reviewers extracted data. Pain and disability were primary outcomes. Pain and disability scores were converted to a scale of 0 (no pain or disability) to 100 (worst pain or disability). A random effects model was used to calculate weighted mean differences and 95% confidence intervals. Safety (any adverse event, serious adverse events, and proportion of participants who withdrew from trials owing to adverse events) was a secondary outcome. Risk of bias was assessed with the Cochrane Collaboration’s tool and certainty of evidence with the grading of recommendations assessment, development and evaluation (GRADE) framework. Results 33 trials (5318 participants) were included. Moderate certainty evidence showed that serotonin-noradrenaline reuptake inhibitors (SNRIs) reduced back pain (mean difference −5.30, 95% confidence interval −7.31 to −3.30) at 3-13 weeks and low certainty evidence that SNRIs reduced osteoarthritis pain (−9.72, −12.75 to −6.69) at 3-13 weeks. Very low certainty evidence showed that SNRIs reduced sciatica at two weeks or less (−18.60, −31.87 to −5.33) but not at 3-13 weeks (−17.50, −42.90 to 7.89). Low to very low certainty evidence showed that tricyclic antidepressants (TCAs) did not reduce sciatica at two weeks or less (−7.55, −18.25 to 3.15) but did at 3-13 weeks (−15.95, −31.52 to −0.39) and 3-12 months (−27.0, −36.11 to −17.89). Moderate certainty evidence showed that SNRIs reduced disability from back pain at 3-13 weeks (−3.55, −5.22 to −1.88) and disability due to osteoarthritis at two weeks or less (−5.10, −7.31 to −2.89), with low certainty evidence at 3-13 weeks (−6.07, −8.13 to −4.02). TCAs and other antidepressants did not reduce pain or disability from back pain. Conclusion Moderate certainty evidence shows that the effect of SNRIs on pain and disability scores is small and not clinically important for back pain, but a clinically important effect cannot be excluded for osteoarthritis. TCAs and SNRIs might be effective for sciatica, but the certainty of evidence ranged from low to very low. Systematic review registration PROSPERO CRD42020158521.
FRI0112 Intravenous pulse cyclophosphamide for lupus nephritis: predictors of remission
Authors: A Tafaj, E Grabocka, A Këlliçi
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Renal involvement in SLE is a common disease manifestation and a strong predictor of poor outcome. The general consensus is that 50% of lupus patients will develop clinically relevant nephritis at some time in the course of their illness. Cyclophosphamide is considered the most effective cytotoxic in the management of lupus renal disease. When used intravenously, cyclophosphamide is less toxic. The risk of haemorrhagic cystitis and permanent gonadal failure with infertility is greater in patients treated with oral cyclophosphamide. Long-term intravenous cyclophosphamide in combination with corticosteroids is the standard therapy for lupus nephritis. <h3>Objectives</h3> The aim of this study was to evaluate the long-term remission rates; predictors of relapse, and the ability to achieve a second remission with currently recommended regimens. <h3>Methods</h3> A cohort of 14 patients (1 male and 13 female) are enrolled into the trial. Mean age is 31.4 years (s.d = 11.9) and median time from diagnosis of SLE is 2 years. The disease severity was evaluated clinically by urinalysis, 24-hour urine protein, hematuria and casts, serum creatinine, and serum complement. We have followed up the patients for a period of 24 months, till now. <h3>Results</h3> The median time to remission was 9 months. From all patients only 4 have relapsed. 3 of them had 24 h proteinura &gt; 3 g before treatment. Time to re-remission not evaluated yet. All patients who relapsed are still under treatment. <h3>Conclusion</h3> A high amount of proteinuria seems to be an adverse predictor of remission. The time to remission was longer in patients with high value of 24 h proteinuria. Our data suggest that a long time to remission is a predictor of earlier relapse. Prolonged courses with cyclophosphamide were needed to achieve remission in many first-treated patients. No data about the duration of treatment in patients who relapsed. No serious toxicity was observed during this study.
SAT0007 Ankylosing spondylitis initiated as a reactive arthritis
Authors: ZA Curcic
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> Objective of this study was to present characteristics of Ankylosing spondilitis (AS), not initiated as genuine (i.e. initiating as a reactive arthritis-ReA). <h3>Methods</h3> The study is a retrospective 20-year analysis of 144 patients treated for ReA. <h3>Results</h3> Spondylitis occurred after either urinary or intestinal infection in 87%; in 53%- following mono- or oligoarthritis. Syndesmophytes of one or more segments were massive, nonmarginal; sacroiliitis-asymmetrical. After the period of 10,6 years, in 25% of diseased, the total spinal column was involved by AS type, with symmetrical sacroiliitis. Some discs presented with calcification resulting from discitis. Some i.v. spaces were reduced including some vertebral bodies which underwent a cuneiform transformation. Postural transformation was less frequent, lumbar lordosis was recorded in 83% with lower frequency of TH kyphosis than in AS. There were cases of interspinal arthrosis and other secondary degenerative transformations. Neurological and/or motorial deficit was recorded in 85% (damage of sensibility, tendon reflexes or motoricity). Function of the spinal column was preserved for the period of 10,5 years on average if the process was of segment character, which referred also to the respiratory function in which the abdominal type of breathing was predominant after 15,5 years. <h3>Conclusion</h3> The presented differences occur for slow process of development of Sp in ReA, because of the involvement of either one or a small number of vertebral units of the spinal column and the presence of discitis, whereas in AS, the course of ossification of the fibres of annulus fibrosus is faster than the destruction of the discus, inner fibres of annulus fibrosus and nucleus pulposus being preserved, in this way the i.v. spaces remain unreduced, not allowing neither discovertebral conflict nor the resulting neurological damage.
No evidence for brown adipose tissue activation after creatine supplementation in adult vegetarians
Authors: Niels J. Connell, Daniel Doligkeit, Charlotte Andriessen, Esther Kornips-Moonen, Yvonne M. H. Bruls, Vera B. Schrauwen-Hinderling, Tineke van de Weijer, Wouter D. van Marken-Lichtenbelt, Bas Havekes, Lawrence Kazak, Bruce M. Spiegelman, Joris Hoeks, Patrick Schrauwen
Journal: Nature Metabolism (2021)
SAT0092 Success-1 in osteoarthritis (oa) trial: celecoxib demonstrates significantly lower hepatic toxicity than diclofenac in the treatment of osteoarthritis
Authors: J Goldstein, G Singh, J Fort, A Bello
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Significant elevations of liver enzymes have been reported in patients taking NSAIDs. Among all NSAIDs, diclofenac and aspirin have been associated with the highest rates of liver toxicity. In previous trials with patients in the US and Canada treated for osteoarthritis (OA), the incidence of hepatic adverse events in patients receiving celecoxib 200 or 400 mg per day was similar to placebo and significantly lower than the incidence for patients receiving diclofenac 100 or 150 mg per day. <h3>Objectives</h3> We compared the hepatic tolerability of celecoxib and the most commonly used regimen of diclofenac in the treatment of OA of the knee, hip, or hand in 13,274 patients enrolled in SUCCESS-1, a multinational, double-blind, randomised trial. <h3>Methods</h3> In the SUCCESS-1 in OA trial, patients with OA from Europe and South Africa, Asia, Latin America, and the US and Canada were evaluated for 12 weeks using fixed dosages of celecoxib 200 mg per day, celecoxib 400 mg per day, or diclofenac 100 mg per day. Patients with pretreatment ALT or AST &gt;/= 3x ULN were excluded. Laboratory tests were obtained at pretreatment and at the final visits. <h3>Results</h3> Overall, patients were mostly female (78%), and had a mean age of 62 (± 10.4) years. Previous daily diclofenac use was comparable (p = 0.57). Clinically meaningful elevations (&gt;/= 3x ULN) in ALT and AST were significantly more frequent in the diclofenac- vs celecoxib-treated patients (p &lt; 0.001) at 12 weeks. In parallel, physician-reported hepatic adverse events, including hepatic dysfunction and increases from pretreatment ALT and AST, were significantly more frequent in patients treated with diclofenac (p &lt; 0.01). <h3>Conclusion</h3> Celecoxib, with its greater hepatic tolerability than the most commonly prescribed regimen of diclofenac, offers a clinical advantage over diclofenac in the management of OA patients. Sponsored by Pharmacia Corporation and Pfizer Inc.
AB0123 Obstructive sleep apnoea (osa) and fatigue in ankylosing spondylitis (as)
Authors: NX Erb, D Karokis, K Raza, M Cushley, GD Kitas
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Fatigue is a common symptom and an indicator of disease activity in AS, but its pathogenic basis is poorly understood.<sup>1</sup> It is also a cardinal symptom of OSA.<sup>2</sup> AS may contribute to OSA through reduction of upper airway size (10% involvement of temporomandibular joints-TMJ), cervical spine (CS) involvement leading to cord or medulla compression, or chest wall involvement leading to poor respiratory pattern. <h3>Objectives</h3> Assessment of the prevalence of OSA in AS and its association with fatigue. <h3>Methods</h3> 22 consenting, random AS out-patients were prospectively recruited. 3 did not attend for assessment. 19 patients [16 males, 3 females; age 43.7 years (31–69)] were assessed using: full clinical examination, Body Mass Index (BMI), Chest, CS and TMJ x-rays, Bath Ankylosing Spondylitis Activity Index (BASDAI), Hospital Anxiety and Depression Scale (HAD), Epworth Sleepiness Scale (ESS), Bed Partner Questionnaire, full Lung Function Tests, sleep studies (2 consecutive nights using EDEN Trace). <h3>Results</h3> 11 patients had normal lung function, 6 had a typical and 2 a borderline restrictive pattern. ESS: mean 10 (2–20). 2 patients (10%) fulfilled criteria for OSA: one had retrognathia, the other no obvious cause. Both received CPAP therapy with great improvement in fatigue and Epworth Sleepiness Scale and normalisation of oximetry. There were no associations with AS duration or activity, HAD, CS involvement, TMJ involvement or BMI. <h3>Conclusion</h3> OSA affects 2% of the general population.<sup>3</sup> Its prevalence in AS appears higher, but no definite conclusions can be drawn from this study. In isolated AS cases, OSA may be an important contributor to fatigue and, in the presence of relevant symptoms, it should be actively investigated and treated. <h3>References</h3> Jones SD, Koh WH, Steiner A, Garrett SL, Calin A. Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol. 1996;23:487–90 Skomro RP, Kryger MH. Clinical presentations of obstructive sleep apnea syndrome. Prog Cardiovasc Dis. 1999;41:331–40 Odens ML, Fox CH. Adult sleep apnea syndromes. Am Fam Physician 1995;<b>52</b>:859–66, 871–2
Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
Authors: Francesco Maura, Benjamin Diamond, Kylee H. Maclachlan, Andriy Derkach, Venkata D. Yellapantula, Even H. Rustad, Malin Hultcrantz, Urvi A. Shah, Jessica Hong, Heather J. Landau, Christine A. Iacobuzio-Donahue, Elli Papaemmanuil, Shani Irby, Laura Crowley, Michael Crane, Mayris P. Webber, David G. Goldfarb, Rachel Zeig-Owens, Orsi Giricz, Amit Verma, David J. Prezant, Ahmet Dogan, Sohrab P. Shah, Yanming Zhang, Ola Landgren
Journal: Clinical Cancer Research (2021)

Abstract Purpose: The World Trade Center (WTC) attack of September 11, 2001 created an unprecedented environmental exposure to known and suspected carcinogens. High incidence of multiple myeloma and precursor conditions has been reported among first responders to the WTC disaster. To expand on our prior screening studies, and to characterize the genomic impact of the exposure to known and potential carcinogens in the WTC debris, we were motivated to perform whole-genome sequencing (WGS) of WTC first responders and recovery workers who developed a plasma cell disorder after the attack. Experimental Design: We performed WGS of nine CD138-positive bone marrow mononuclear samples from patients who were diagnosed with plasma cell disorders after the WTC disaster. Results: No significant differences were observed in comparing the post-WTC driver and mutational signature landscapes with 110 previously published WGSs from 56 patients with multiple myeloma and the CoMMpass WGS cohort (n = 752). Leveraging constant activity of the single-base substitution mutational signatures 1 and 5 over time, we estimated that tumor-initiating chromosomal gains were windowed to both pre- and post-WTC exposure. Conclusions: Although limitations in sample size preclude any definitive conclusions, our findings suggest that the observed increased incidence of plasma cell neoplasms in this population is due to complex and heterogeneous effects of the WTC exposure that may have initiated or contributed to progression of malignancy.
SAT0011 Association of phenotypic expression of ankylosing spondylitis (as) with the presence of hla-b60 antigen
Authors: SN Tchepeleva, GV Loukina
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To investigate the association of hip and eyes involvement with the presence of HLA-B60 antigen in AS patients. <h3>Methods</h3> HLA-B60-typing was performed in 49 AS patients (all patients fulfilled the New York criteria for AS): 14 female and 35 male; mean age 38,8 years, mean disease duration 15,3 years. The diagnosis of anterior uveitis was verified by an ophthalmologist. Pelvic X-rays, ultrasonography of joints and densitometry were performed to estimate the hip involvement. Periarticular osteoporosis, joint space narrowing (&lt;4 mm), osteophytes, cysts, erosive changes, aseptic necrosis of the femoral head, thickness of the synovial membrane and hip joint effusion were considered as the features of hip involvement. <h3>Results</h3> 5 (10,2%) of 49 patients were B60-positive. 44 patients (89,8%) were B60-negative. 13 patients (26,5%) had anterior uveitis. All of them were B60-negative. The hip involvement was observed in 100% of B60-negative and in 80% of B60-positive AS patients. <h3>Conclusion</h3> Our results consent to other authors? data about the less hip and eyes involvement in HLA-B60-positive AS patients. Further investigation is needed to confirm these results on the greater patient group.
Heritability of sleep duration and quality: A systematic review and meta-analysis
Authors: Desana Kocevska, Nicola L. Barclay, Wichor M. Bramer, Philip R. Gehrman, Eus J.W. Van Someren
Journal: Sleep Medicine Reviews (2021)

Epidemiological and interventional research has highlighted sleep as a potentially modifiable risk factor associated with poor physical and mental health. Emerging evidence from (behavioral) genetic research also shows that sleep characteristics are under strong genetic control. With this study we aimed to meta-analyze the literature in this area to quantify the heritability of sleep duration and sleep quality in the general population. We conducted a systematic literature search in five online databases on January 24th 2020. Two authors independently screened 5644 abstracts, and 160 complete articles for the inclusion criteria of twin studies from the general population reporting heritability statistics on sleep duration and/or quality, and written in English. We ultimately included 23 papers (19 independent samples: 45,328 twins between 6 mo and 88 y) for sleep duration, and 13 papers (10 independent samples: 39,020 twins between 16 and 95 y) for sleep quality. Collectively, we showed that 46% of the variability in sleep duration and 44% of the variability in sleep quality is genetically determined. The remaining variation in the sleep characteristics can mostly be attributed to the unique environment the twins experience, although the shared environment seemed to play a role for the variability of childhood sleep duration. Meta-analyzed heritability estimates for sleep duration, however, varied substantially with age (17% infancy, 20–52% childhood, 69% adolescence and 42–45% adulthood) and reporter (8% parent-report, 38–52% self-report). Heritability estimates for actigraphic and Polysomnography (PSG)-estimated sleep were based on few small samples, warranting more research. Our findings highlight the importance of considering genetic influences when aiming to understand the underlying mechanisms contributing to the trajectories of sleep patterns across the lifespan.
SP0062 Fibromyalgia: evidence for a central nervous system disorder
Authors: L Bradley
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> This presentation reviews evidence from several studies in our laboratory regarding central factors associated with abnormal pain sensitivity in fibromyalgia (FM). We have found that, compared to healthy controls, clinic patients with FM and community residents who meet criteria for FM but have not consulted a physician (FM non-patients) display significantly lower pain thresholds in response to pressure stimulation and exhibit significantly higher cerebrospinal fluid (CSF) levels of substance P. In addition, during exposure to suprathreshold levels of pressure stimulation, controls and FM patients differ in changes in brain regional cerebral blood flow (rCBF). That is, controls show significant rCBF increases in the contralateral thalamus, somatosensory cortex, and the anterior cingulate cortex, whereas patients with FM show significant and bilateral increases in rCBF in these brain structures. Finally, patients with FM show greater cardiovascular responses to stress than controls. Moreover, stress produces greater increases in thermal pain unpleasantness ratings among FM patients compared to controls. Together, these findings indicate that FM patients show abnormal central processing of nociceptive stimuli that tends to be exacerbated by stress. We plan to determine whether the effects of stress on pain unpleasantness in FM (a) are associated with abnormal rCBF changes in the anterior cingulate cortex; and (2) may be mediated by abnormal cortisol release or cytokine production. <h3>References</h3> Aaron LA, Bradley LA, Alarcon GS, <i>et al</i>. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum. 1996;39:436–45 Bradley LA, Alarcon GS. Fibromyalgia. In: Koopman WJ, ed. <i>Arthritis and allied conditions</i>: a textbook of rheumatology. 14th edn. Baltimore, MD: Williams &amp; Wilkins, 2001 Bradley LA, McKendree-Smith NL, Alarcon GS. Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome. Curr Rev Pain 2000;4:148–57 Bradley LA, McKendree-Smith NL, Alberts KR, Alarcon GS, Mountz JM, Deutsch G. Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Curr Rheumatol Rep. 2000;2:141–8 Bradley LA, Sotolongo A, Alberts KR, <i>et al</i>. Abnormal regional cerebral blood flow in the caudate nucleus among fibromyalgia patients and non-patients is associated with insidious symptom onset. J Musculoskeletal Pain 1999;7:285–92 Mountz JM, Bradley LA, Modell JG, <i>et al</i>. Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 1995;38:926–38 Pillemer SR, Bradley LA, Crofford LJ, <i>et al</i>. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum. 1997;40:1928–37